RESEARCH STUDIES & Clinical Trials

Clinical Trial ID: NCT03926624 Phase III Randomized Trial of DFP-10917 vs. Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine) or Intensive Reinduction (High and termediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patients in Second or Third Salvage

Status

Open

Description

This is a Phase III, multicenter, randomized, controlled study to compare the rate of CR and duration of CR, in patients with relapsed or refractory AML to a prior intensive chemotherapy regimen (e.g., "7+3" cytarabine and daunorubicin) or to an epigenetic therapy (i.e., azacitidine or decitabine), who will receive DFP-10917 versus LoDAC or azacitidine as a first-salvage treatment.

Objective

The primary objective is to compare the rate of Complete Remission (CR) and duration of CR, in patients who receive DFP-10917 versus non-intensive reinduction (LoDAC, azacitidine, decitabine) or intensive reinduction (high and intermediate dose cytarabine regimens) as second or third salvage treatment.

Treatment

Experimental Arm; DFP-10917 14-day continuous intravenous (IV) infusion at a dose of 6 mg/m2/day followed by a 14-day resting period per 28-day cycles. If a patient experiences a significant treatment-related adverse event (AE), the patient may undergo one dose reduction of DFP-10917 to 4 mg/m2/day x 14 days for subsequent treatment cycles. Active Comparator: LoDAC or Azacitidine • LoDAC: Cytarabine at 20 mg administered subcutaneously (SC) twice daily (BID) for 10 days, plus best supportive care per 28-day treatment cycle. • Azacitidine: 75 mg/m2/day administered SC for 7 days, plus best supportive care per 28-day treatment cycle.

Conditions

Other

Phases

III

Therapies

Drugs

Age Group

Adult

Main Investiagtor

Hammond, William

Practice

Heme

Scope

National

Participating Institutions

Baptist MD Anderson Cancer Center

Eligibility

Inclusion Criteria: - Histologically or pathologically confirmed diagnosis of AML based on WHO classification that has relapsed after, or is refractory to, a prior intensive chemotherapy regimen (e.g., "7+3" cytarabine and daunorubicin) or epigenetic therapy (i.e., azacitidine or decitabine). - Aged > 18 years. - ECOG Performance Status of 0, 1 or 2. - Adequate clinical laboratory values (i.e., plasma creatinine < 2.5 x upper limit of normal (ULN) for the institution, bilirubin < 2.5 x ULN, alanine transaminase (ALT) and aspartate transaminase (AST) < 2.5 x ULN). - Absence of active central nervous system (CNS) involvement by leukemia. Patients with previously diagnosed CNS leukemia are eligible if the CNS leukemia is under control and intrathecal treatment may continue throughout the study. - Absence of uncontrolled intercurrent illnesses, including uncontrolled infections, cardiac conditions, or other organ dysfunctions. - Signed informed consent prior to the start of any study specific procedures. - Women of child-bearing potential must have a negative serum or urine pregnancy test. - Male and female patients must agree to use acceptable contraceptive methods for the duration of the study and for at least one month after the last drug administration. Exclusion Criteria: - The interval from prior treatment to time of study drug administration is < 2 weeks for cytotoxic agents or < 5 half-lives for noncytotoxic agents. Exceptions: Use of hydroxyurea is allowed before the start of study and is to be discontinued prior to randomization. - Patients with first leukemia remission >24 months. - Prior leukemia salvage therapy following relapsed disease or following failed first induction. - Suitable for and willing to receive intensive re-induction chemotherapy (e.g., "7+3", MEC, FLAG, HiDAC). - Any >grade 1 persistent clinically significant toxicities from prior chemotherapy. - Cardiac (left ventricular ejection fraction < 40%) function. - White blood cell (WBC) count >15,000/uL. - Any concomitant condition that in the opinion of the investigator could compromise the objectives of this study and the patient's compliance. - A pregnant or lactating woman. - Current malignancies of another type. Exceptions: Patients may participate if they have previously treated and currently controlled prostate cancer, adequately treated in situ cervical cancer and basal cell skin cancer or other malignancies with no evidence of disease for 2 years or more. - Patient has acute promyelocytic leukemia (APL). - Patients with known HIV, HBV or HCV infection (note: testing for these infections is not required). - Documented or known clinically significant bleeding disorder.

Nct ID Number

NCT03926624

Secondary Trial ID Number

D18-11141/DELTA-FLY

Keywords

Treatment

More Information

clinicaltrials.gov

“The support team gave not only me but my family a sense of peace.”

—David Smith, Patient

At Baptist MD Anderson, you can rely on our cancer experts to deliver the complex, coordinated care needed to address your condition. Learn more about Patricia’s story as well as others from our patients.